Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on April 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 24, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• A total of 14,900 shares were sold in multiple transactions at varying prices.
• The prices ranged from $106.65 to $110.25 per share.
• Following the reported transactions, Afeyan directly owns 2,041,931 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to insider trading under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment, but rather a procedural disclosure.

Industry Context

Sales by insiders are a common occurrence, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to sell shares over a period of time without being accused of trading on non-public information. The market typically views these sales in the context of the overall trading plan and the insider's remaining holdings.

Comparison to Industry Standards

• Comparing insider sales activity to other biotech companies of similar market capitalization, such as BioNTech or Regeneron, can provide context.
• Reviewing the frequency and volume of insider sales in these companies can help determine if the Moderna director's sales are within a typical range.
• Analyzing the percentage of total holdings sold by insiders in comparable companies can also offer a benchmark.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the existence of the 10b5-1 trading plan.
• The impact on employees, customers, suppliers, and creditors is expected to be negligible.

Key Dates